Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a new condition term, Primary peritoneal carcinoma, and a new external resource (Genetic and Rare Diseases Information Center) for patient education. The page update also includes a new Revision (v3.4.2) and removal of the prior funding-notice (v3.4.1).SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a government funding notice indicating the NIH Clinical Center is open. Updated the page to Revision: v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary toggle and updated the revision label to v3.4.0, with minor capitalization and wording adjustments to metadata. These changes are cosmetic and do not alter the study content.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This appears to be a minor internal update with no impact on study details or user interactions.SummaryDifference0.1%

- Check63 days agoChange DetectedDifference0.3%

- Check92 days agoChange DetectedA new revision number v3.3.2 is shown, replacing the previous v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.